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STEATOHEPATITIS/METABOLIC LIVER DISEASE
CX3CR1 Is a Gatekeeper for Intestinal Barrier Integrity
in Mice: Limiting Steatohepatitis by Maintaining
Intestinal Homeostasis
Kai Markus Schneider,1* Veerle Bieghs,1* Felix Heymann,1 Wei Hu,1 Daniela Dreymueller,2 Lijun Liao,1
Mick Frissen,1 Andreas Ludwig,2 Nikolaus Gassler,3 Oliver Pabst,4 Eicke Latz,5,6,7 Gernot Sellge,1
John Penders,8 Frank Tacke,1 and Christian Trautwein1
Nonalcoholic fatty liver disease is seen as the hepatic manifestation of the metabolic syn-
drome and represents the most common liver disease in Western societies. The G protein–
coupled chemokine receptor CX3CR1 plays a central role in several metabolic syndrome–
related disease manifestations and is involved in maintaining intestinal homeostasis. Because
diet-induced intestinal dysbiosis is a driver for nonalcoholic fatty liver disease, we hypothe-
sized that CX3CR1 may influence the development of steatohepatitis. In two independent
models of diet-induced steatohepatitis (high-fat diet and methionine/choline-deficient diet),
CX3CR1 protected mice from excessive hepatic steatosis and inflammation, as well as sys-
temic glucose intolerance. Lack of Cx3cr1 expression was associated with significantly altered
intestinal microbiota composition, which was linked to an impaired intestinal barrier. Con-
comitantly, endotoxin levels in portal serum and inflammatory macrophages in liver were
increased in Cx3cr1–/– mice, indicating an increased inflammatory response. Depletion of
intestinal microbiota by administration of broad-spectrum antibiotics suppressed the num-
ber of infiltrating macrophages and promoted macrophage polarization in liver. Conse-
quently, antibiotic-treated mice demonstrated a marked improvement of steatohepatitis.
Conclusion: Microbiota-mediated activation of the innate immune responses through
CX3CR1 is crucial for controlling steatohepatitis progression, which recognizes CX3CR1 as
an essential gatekeeper in this scenario. (HEPATOLOGY 2015;62:1405-1416)
N
onalcoholic fatty liver disease covers a broad
spectrum of diseases ranging from steatosis to
nonalcoholic steatohepatitis (NASH). NASH
is characterized by steatosis in combination with inflam-
mation and can further progress to fibrosis and hepatocel-
lular carcinoma.1 NASH is associated with the metabolic
syndrome, and due to the obesity epidemic, the incidence
of NASH is rising dramatically.2,3 However, not all obese
people develop NASH and lean persons can also suffer
from steatohepatitis,4 indicating that additional causes,
such as genetic and environmental factors, may be
involved in the transition from steatosis to NASH.
Abbreviations: ALT, alanine aminotransferase; BMDM, bone marrow–derived macrophage; FACS, fluorescence-activated cell sorting; FKN, fractalkine; HFD,
high-fat diet; Il1b/Il1b, interleukin 1-beta; MCD, methionine/choline-deficient; Mcp1, monocyte chemoattractant protein 1; NAS, nonalcoholic fatty liver disease
activity score; NASH, nonalcoholic steatohepatitis; NCD, normal control diet; PAMP, pathogen-derived molecular pattern; TLR, toll-like receptor; WT, wild type.
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The chemokine receptor CX3CR1 (also known as
GPR-13) has been linked to metabolic syndrome–
related diseases, including diabetes,5 obesity,6 and ather-
osclerosis.7,8 Due to cleavage of the extracellular
domain, higher circulating levels of fractalkine (FKN)
are linked to onset of the metabolic syndrome.6 Interest-
ingly, it is thought that intestinal barrier dysfunction as
well as intestinal dysbiosis are also associated with
these metabolic disorders.9-11 Intestinal macrophages are
defined by their expression of CX3CR1, and MHCIIhi
CD11b1CD11c1F4/801CX3CR1hi macrophages in the
gut are critical for intestinal barrier integrity. These cells
have a high phagocytic capacity and limit translocation of
pathogen-derived molecular patterns (PAMPs) as well as
microbiota-derived molecular patterns.12,13 Recently, it has
been demonstrated that Cx3cr1–/– mice have decreased
numbers of these mucosal resident macrophages, show
increased bacterial translocation to mesenteric lymph
nodes, and have increased susceptibility to dextran sodium
sulfate–induced colitis.14 Moreover, CX3CR1 mediates
direct protective effects on intestinal epithelial cells, includ-
ing autocrine regulation of cell-survival signals and activa-
tion of immune modulators.15
During the pathogenesis of steatohepatitis, transloca-
tion of PAMPs plays a critical role in murine disease mod-
els.16,17 Indeed, recent data indicate that also patients
suffering from steatohepatitis have a disturbed intestinal
barrier, suggesting an essential role of this mechanism in
human disease manifestations.18 The intestinal barrier is
formed by a single layer of intestinal epithelial cells, which
are interconnected by tight junctions and covered by
mucus.19 Therefore, loss of tight junctions as a result of
intestinal dysbiosis facilitates gut leakiness and transloca-
tion of PAMPs to the liver. Increased numbers of PAMPs
in the venous circulation of the gut can activate pathogen
recognition receptors, such as Toll-like receptors
(TLRs) and multiprotein inflammasome complexes
and thereby trigger an inflammatory response that
contributes to the development and progression of
steatohepatitis.20,21
Here, we investigated how CX3CR1 regulates intesti-
nal microbiome homeostasis and thereby influences
diet-induced steatohepatitis. Our present work suggests
that CX3CR1 is an essential gatekeeper in microbiota-
mediated activation of the innate immune response and
consequently progression of steatohepatitis.
Materials and Methods
Mouse Experiments. All animal experiments were
approved by the appropriate German authorities
(LANUV, North Rhine-Westphalia, Az 84-02.04.
2012.A260). All animals received humane care according
to the criteria outlined in the “Guide for the Care and Use
of Laboratory Animals” prepared by the National Acad-
emy of Sciences and published by the National Institutes
of Health (publication 86-23, revised 1985). C57BL/6
wild-type (WT) and Cx3cr1-deficient (Cx3cr1–/–) mice
(C57BL/6 background) were housed in filter-top cages.
The Cx3cr1–/– mice had green fluorescent protein inserted
into the CX3CR1 genetic locus.22 All experiments were
performed in 6-week-old to 8-week-old male mice. Two
different dietary models were used to induce steatohepati-
tis—16 weeks of 60% high-fat diet (HFD; WT n 5 5
and CX3CR1–/– n 5 4; D12492; Research Diet Services
BV, Gentofte, Denmark) and 8 weeks of methionine/chol-
ine-deficient diet (MCD; WT n 5 7 and CX3CR1–/–
n 5 6; 960439; MP Biomedicals, Heidelberg, Germany).
A normal chow diet (NCD) was used as a control diet
(both WTand Cx3cr1–/– mice n 5 2).
Collection of blood and tissue specimens, biochemi-
cal determination of liver lipids, caspase 3 activity assay,
RNA isolation, complementary DNA synthesis, quanti-
tative polymerase chain reaction, and serum parameters
(aminotransferases, glutamate dehydrogenase, and alka-
line phosphatase) were determined as described.23,24
Administration of broad-spectrum antibiotics, isolation
of intestinal epithelial and lamina propria cells, oral glu-
cose tolerance test, endotoxin measurement, histology,
microbiota data analysis, fluorescence-activated cell sort-
ing (FACS), immunoblotting, cell culture experiments,
and statistical analysis are described in detail in the Sup-
porting Information.
Results
Cx3cr1 Deletion Triggers Progression of Diet-
Induced Steatohepatitis. To investigate the relevance
of CX3CR1 for the progression of diet-induced steato-
hepatitis, we fed WT and Cx3cr1–/– mice two different
Address reprint requests to: Veerle Bieghs, Ph.D., Department of Internal Medicine III, University Hospital, RWTH Aachen, Pauwelsstraß e, 30, Aachen 52074,
Germany. E-mail: veerlebieghs@hotmail.com; tel: 10241-80-80662; fax: 10241-80-82455.
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experimental diets (HFD [16 weeks] and MCD [8
weeks] diet). HFD and MCD feeding induced more
severe hepatic steatosis in Cx3cr1–/– compared to WT
mice, evidenced by increased lipid accumulation shown
by hematoxylin and eosin and oil red O staining (Fig.
1A,B) as well as hepatic triglyceride levels (Fig. 1C). In
addition, Cx3cr1–/– mice had a higher histopathological
nonalcoholic fatty liver disease activity score (NAS),
higher serum levels of liver injury markers glutamate
dehydrogenase and alanine aminotransferase (ALT), and
a higher liver-to-body weight ratio (Fig. 1D). In con-
trast, the body weight did not differ between the groups
(Supporting Fig. S1A).
Additionally, Cx3cr1–/– mice showed higher fasting
glucose levels as well as decreased oral glucose tolerance
in comparison to WT mice after HFD feeding but not
to control fed mice (Fig. 1E). These data indicate that
upon dietary challenge Cx3cr1–/– mice have impaired
glucose metabolism.
The MCD diet furthermore induced increased cell
death in livers of Cx3cr1–/– mice because we identified
higher numbers of terminal deoxynucleotidyl transfer-
ase–mediated deoxyuridine triphosphate nick-end label-
ing–positive and cleaved caspase-3-positive cells
(Supporting Fig. S2A), increased caspase-3 activity
(Supporting Fig. S2B), as well as ballooning hepatocytes
(Supporting Fig. S1D,E) compared to WT mice. In
addition, sirius red staining revealed increased pericellu-
lar fibrosis upon MCD feeding in Cx3cr1–/– mice com-
pared to WT mice (Supporting Fig. S2C). Expression of
fibrosis-related genes such as collagen type 1 alpha 1
(Col1a1), transforming growth factor beta, and alpha-
smooth muscle actin (Supporting Fig. S2D) was found
to be increased after MCD diet in Cx3cr1–/– mice com-
pared to WT mice. Altogether, these data indicate that
lack of Cx3cr1 expression results in more severe liver
injury and is associated with systemic glucose intoler-
ance upon diet-induced steatohepatitis in mice.
CX3CR1 Controls the Inflammatory Response
During Diet-Induced Steatohepatitis. Next, we
investigated the relevance of CX3CR1 for hepatic
inflammation during diet-induced steatohepatitis.
Fig. 1. Liver injury and glucose intolerance upon diet-induced steatohepatitis. (A) Hematoxylin and eosin staining, (B) oil red O staining, and (C) tri-
glyceride levels in livers of WT and Cx3cr1–/– mice on NCD, HFD, and MCD. (D) NAS, serum glutamate dehydrogenase and ALT levels, and liver-to-body
weight ratio in WT and Cx3cr1–/– mice on NCD, HFD, and MCD. (E) Oral glucose tolerance test and area under the curve after 0, 15, 30, 60, and 120
minutes. Data are expressed as the mean 6 standard error of the mean and considered significant at *P< 0.05, **P< 0.01, and ***P< 0.001.
*Significantly different from the resp. control group upon NCD, unless indicated differently. Abbreviations: AUC, area under the curve; GLDH, glutamate
dehydrogenase; HE, hematoxylin and eosin; OGTT, oral glucose tolerance test; ORO, oil red O; TG, triglyceride.
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Immunohistochemical staining against CD45 revealed
more infiltration of immune cells in livers of Cx3cr1–/–
mice compared to WT controls after both HFD and
MCD (Fig. 2A). Additionally, FACS analysis demon-
strated that inflammatory macrophages (defined as
CD11bhiF4/80low) were the predominant infiltrating
cell type (Fig. 2B). Immunostaining against CD11b in
livers of Cx3cr1–/– mice revealed that these clusters of
inflammatory cells were CD11b-positive (Fig. 2C).
Stronger immune cell infiltration in livers of Cx3cr1–/–
mice was associated with higher gene expression of the
proinflammatory cytokines tumor necrosis factor alpha
and monocyte chemoattractant protein 1 (Mcp1) (Fig.
2D), which are known to aggravate steatohepatitis.25
This difference was already apparent on NCD, indicat-
ing basal inflammatory differences between WT and
Cx3cr1–/– mice. Hence, these data demonstrate that
CX3CR1 is involved in limiting the inflammatory
response during diet-induced steatohepatitis.
Alterations in Gut-Microbiota Composition of
Cx3cr1–/– Mice. Steatohepatitis is associated with
intestinal dysbiosis; therefore, we next analyzed the
effect of Cx3cr1 deletion on the composition of the
intestinal microbiota. Because the MCD diet is not
physiological in terms of mimicking the metabolic situa-
tion during steatohepatitis development, we decided to
continue with the HFD model for the analysis of the
intestinal microbiota. Metagenomic DNA from cecal
microbiome samples was used to generate amplicons of
the V1-V3 hypervariable region of the 16S ribosomal
RNA gene (rDNA) and sequenced using the 454 tech-
nology. Sixteen weeks of HFD resulted in marked altera-
tions in both WT and Cx3cr1–/– mice, reflecting the
microbial diversity within the individual groups (Fig. 3A;
Supporting Fig. S3A,B). These results are also in line
with the clustering according to genotype and diet in the
principal coordinate analysis graph (Supporting Fig.
S3C), indicating that HFD induced more pronounced
changes in microbiota composition of Cx3cr1–/– mice
compared to WT controls, which was also reflected by
beta-diversity metrics (Supporting Fig. S3D).
To identify bacteria that define the key differences
between the experimental groups, we computed a clus-
tering analysis based on relative genus abundances. Inter-
estingly, this analysis identified the bacterial genus
Akkermansia as the defining bacteria for WT NCD mice,
while Bacteroides was the major genus driving the parti-
tioning in the Cx3cr1–/– HFD group (Fig. 3A). These
data were confirmed by heatmap analysis, including the
40% most abundant genera (Supporting Fig. S4).
Fig. 2. Inflammatory responses in diet-induced liver injury. (A) Immunohistochemical staining against CD45 in livers of WT and Cx3cr1–/– mice
on HFD and MCD. (B) Flow-cytometric analysis of infiltrating inflammatory macrophages (CD11bhiF4/80low) in livers of WT and Cx3cr1–/– mice on
NCD, HFD, and MCD. (C) Hematoxylin and eosin and immunofluorescent staining against CD11b in livers of Cx3cr1–/– mice. (D) Hepatic gene
expression of the proinflammatory cytokines tumor necrosis factor-alpha and monocyte chemoattractant protein 1 in WT and Cx3cr1–/– mice on
NCD, HFD, and MCD. Data are expressed as the mean 6 standard error of the mean and considered significant at *P< 0.05, **P< 0.01, and
***P< 0.001. *Significantly different from the resp. control group upon NCD, unless indicated differently. Abbreviations: DAPI, 40,6-diamidino-2-
phenylindole; HE, hematoxylin and eosin; Mcp1, monocyte chemoattractant protein 1; Tnf, tumor necrosis factor-alpha.
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Because Akkermansia muciniphila is linked to intestinal
barrier integrity and especially mucus production,26,27 we
evaluated the mucus layers in more detail. This analysis
revealed that Cx3cr1–/– mice have thinner mucus layers in
colon compared to WTmice (Fig. 3B). Additionally, HFD
feeding led to reduced expression of the tight junction pro-
teins zonula occludens 1 and occludin (Fig. 3C) in both
ileum and colon of Cx3cr1–/– mice compared to WT con-
trols. Together, these data indicate that CX3CR1 is
involved in regulating intestinal barrier integrity.
Fig. 3. Gut-microbiota composition and intestinal barrier integrity upon HFD. (A) Pie chart of multitag pyrosequencing data analyzed at the phylum level in
WT and Cx3cr1–/– mice on NCD and HFD. Uncommon phyla that are a very small fraction of the total may not be visible in the chart even though they are
present in the legend. Relative abundance of the bacterial genera Akkermansia and Bacteroides in WT and Cx3cr1–/– mice on NCD and HFD. (B) Immunoflu-
orescent staining against Mucin-2 and quantification of the mucus thickness in colon samples of WT and Cx3cr1–/– mice. (C) Immunofluorescent staining
and immunoblotting against the tight junction proteins zonula occludens 1 and occludin in colon and ileum of WT and Cx3cr1–/– mice. (D) Flow-cytometric
analysis of colon lamina propria cells of the CD11b1CD11c1 macrophage subset, phagocytic capacity, and the CD11b1CD11c– macrophage subset in WT
and Cx3cr1–/– mice on NCD and HFD (gating strategy Supporting Fig. S4A). (E) Immunofluorescent staining against CD11b in ileum of WT and Cx3cr1–/–
mice on NCD and HFD. (F) Portal endotoxin levels in WT and Cx3cr1–/– mice upon HFD. Data are expressed as the mean 6 standard error of the mean and
considered significant at *P< 0.05, **P< 0.01, and ***P< 0.001. *Significantly different from the resp. control group upon NCD, unless indicated differ-
ently. Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ZO-1, zonula occludens 1.
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Reduced Number of Intestinal Resident Macro-
phages and Increased Bacterial Translocation in
Cx3cr1–/– Mice Upon HFD. Because resident macro-
phages in the gut (defined as CX3CR1hiCD11b1
CD11c1F4/801) have a gatekeeper function for the
intestinal barrier, we analyzed colon lamina propria cells
by FACS (gating strategy Supporting Fig. S5A). We
observed basal differences in resident macrophages
between WT and Cx3cr1–/– mice, which was associated
with an overall decreased phagocytic capacity in
Cx3cr1–/– mice (Fig. 3D). Furthermore, HFD induced a
decrease in this specific macrophage subset in WT mice,
while this did not further decrease in Cx3cr1–/– mice
(Fig. 3D).
Additionally, CD11b1CD11c– macrophages were
reduced in Cx3cr1–/– mice upon HFD compared to WT
mice (Fig. 3D). These findings were confirmed by stain-
ing against CD11b, showing a reduction of CD11b1
cells in the ileum, which was more pronounced in
Cx3cr1–/– mice upon HFD (Fig. 3E). In line with these
findings, WT and Cx3cr1–/– mice showed decreased
expression of tumor necrosis factor-alpha, Mcp1, and
Ccl5 in ileum after 16 weeks of HFD (Supporting Fig.
S5B). These differences were also associated with
changes in localization of CD11b1 cells in ileum. While
CD11b1 cells had an equal distribution throughout the
villi in WT mice upon HFD, these cells were mainly
localized at the basement of the villi in Cx3cr1–/– mice
(Fig. 3E). The observed phenotype was not due to a
reduction of circulating Ly6Chi classical monocytes
(Supporting Fig. S5C), indicating that CX3CR1 mainly
affects intestinal cell differentiation or recruitment.
Finally, to assess whether the impaired intestinal bar-
rier also leads to higher translocation of PAMPs, we ana-
lyzed the endotoxin levels in portal vein serum from
mice upon HFD. We found more endotoxin in
Cx3cr1–/– mice compared to WT mice upon HFD (Fig.
3F), indicating increased translocation of bacterial prod-
ucts from the gut into the portal circulation.
CX3CR1 Can Regulate Innate Immune Signaling
in Macrophages. Our data are consistent with an
involvement of CX3CR1 in the maintenance of intesti-
nal homeostasis and the physiological architecture of the
lamina propria. To investigate the role of CX3CR1 sig-
naling in macrophages in general, we prepared bone
marrow–derived macrophages (BMDMs) of WT and
Cx3cr1–/– mice. Resting BMDMs of Cx3cr1–/– mice dis-
played characteristics of preactivation, as shown by an
elevated phagocytic capacity (Fig. 4A). Because resident
intestinal macrophages are regularly exposed to high lev-
els of PAMPs, we investigated the role of CX3CR1 in
innate immune responses toward PAMPs. Cx3cr1–/–
BMDMs released higher amounts of IL1b upon inflam-
masome stimulation (lipopolysaccharide 1 nigericin)
compared to WT BMDMs (Fig. 4B). In addition, gene
expression of Nlrp3, Caspase 1, and Il1b were increased
in Cx3cr1–/– BMDMs upon inflammasome stimulation
compared to WT BMDMs (Fig. 4C). By incubating
NLRP3 macrophage reporter cells with CX3CL1
(FKN) before stimulation with nigericin, we observed
that FKN suppressed inflammasome activation, which
was also reflected by a decreased expression of IL1b in
supernatant (Fig. 4D). Furthermore, WT and Cx3cr1–/–
BMDMs released equal amounts of FKN in supernatant
(Fig. 4E), and upon blocking FKN signaling with a neu-
tralizing antibody WT and Cx3cr1–/– BMDMs showed
an equal response to inflammasome stimulation (Fig.
4F). Hence, our in vitro experiments identified
CX3CR1 as a regulator of the innate immune response
through inflammasome signaling.
Administration of Broad-Spectrum Antibiotics
Dampens Steatohepatitis and Restores Glucose Toler-
ance in Cx3cr1–/– Mice Upon HFD. Because
Cx3cr1–/–-derived BMDMs showed an aggravated
response toward inflammasome stimulation, we tested
whether eradication of the intestinal microbiota using
broad-spectrum antibiotics had an impact on the pro-
gression of steatohepatitis. Antibiotic treatment in com-
bination with HFD did not induce a difference in
weight gain between WT and Cx3cr1–/– mice (Support-
ing Fig. S6E). However, antibiotic treatment signifi-
cantly ameliorated steatohepatitis in Cx3cr1–/– mice to
similar levels as WT mice (Fig. 5A), as indicated by an
improved NAS, liver-to-body weight ratio, lower ALT
levels, and a reduced number of CD45-positive cells
(Supporting Fig. S6B). In addition, eradication of the
intestinal microbiota improved hepatic steatosis (Fig.
5A,B) and glucose intolerance (Fig. 5C). Notably,
Cx3cr1–/– mice had normal fasting glucose levels, sug-
gesting that alterations in the microbial composition
directly affect insulin resistance.
Antibiotic Treatment Dampens the Innate
Immune Response in Cx3cr1–/– Mice and Affects
Macrophage Polarization. We next investigated the
effect of antibiotic treatment on the innate immune
response in the liver. HFD significantly increased TLR4
protein and messenger RNA expression in WT and
Cx3cr1–/– livers (Fig. 6A). Antibiotic treatment reduced
TLR4 expression in both groups. Besides TLR4, HFD
also induced the expression of Nlrp3 and Casp1, which
were significantly higher in Cx3cr1–/– mice compared to
WT controls (Fig. 6B). In line with these findings,
hepatic Il1b levels were also increased in Cx3cr1–/– mice
upon HFD compared to WT controls (Fig. 6B).
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Interestingly, antibiotic treatment was able to reduce the
HFD-induced innate immune response in livers of
Cx3cr1–/– mice (Fig. 6A,B).
Additionally, antibiotic treatment influenced the infil-
tration of CD11b1 inflammatory macrophages (Fig.
6C,D) and reduced the expression of Mcp1 in livers of
Cx3cr1–/– mice upon HFD (Fig. 6E). FACS analysis
revealed that eradication of the intestinal microbiota
dampened the infiltration of inflammatory CD11bhiF4/
801 macrophages and induced a shift toward the
“restorative” surface markers CD2061 and CD1241 on
these cells (Fig. 6F). Altogether, these data suggest that
intestinal dysbiosis in Cx3cr1–/– mice triggers activation
of proinflammatory liver macrophages, thereby stimu-
lating disease progression of steatohepatitis.
Discussion
The gut–liver axis plays an important role in the
pathogenesis of chronic liver disease.16,20 However, the
Fig. 4. Innate immune signaling in BMDMs. (A) Phagocytic capacity of WT and Cx3cr1–/– BMDMs. (B) Il1b levels in supernatant of WT and
Cx3cr1–/– BMDMs upon inflammasome stimulation (LPS 1 nigericin). (C) Gene expression of Nlrp3, Casp1, and Il1b in BMDMs upon inflamma-
some stimulation (LPS 1 nigericin). (D) Inflammasome stimulation of macrophage reporter cells with and without FKN (0.03 nM) and immuno-
blotting of Il1b in supernatant of WT and Cx3cr1–/– BMDMs upon inflammasome stimulation with and without FKN (0.03 nM). (E) FKN levels in
supernatant of WT and Cx3cr1–/– BMDMs. (F) Il1b levels in supernatant of WT and Cx3cr1–/– BMDMs upon inflammasome stimulation (LPS 1 ni-
gericin) in combination with a CX3CL1 antibody or isotype control. Data are expressed as the mean 6 standard error of the mean and consid-
ered significant at *P< 0.05, **P< 0.01, and ***P< 0.001. *Significantly different from the resp. control group upon NCD, unless indicated
differently. Abbreviations: LPS, lipopolysaccharide; PE, phycoerythrin; ASC, Apoptosis-associated speck-like protein containing a CARD.
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exact contribution of the intestinal barrier and dysbiosis
to steatohepatitis pathogenesis and its potential thera-
peutic implications remain unclear.28 In the current
study, we investigated the contribution of CX3CR1 in
controlling gut–liver interactions during progression of
diet-induced steatohepatitis. We demonstrated that
CX3CR1 signaling is crucial in the maintenance of
intestinal homeostasis during steatohepatitis by main-
taining intestinal barrier integrity. Therefore, our data
identified CX3CR1 as a gatekeeper of steatohepatitis.
The concept that intestinal inflammation acts as an
important driver for liver diseases was initially inspired
by observations in patients suffering from inflammatory
bowel disease, who often present elevated transami-
nases.29,30 Interestingly, the two single-nucleotide poly-
morphisms (T280M and V249I) in the coding sequence
of CX3CR1, which confers functionally reduced binding
of FKN to its receptor, have been associated with
Crohn’s disease, suggesting more inflammatory activ-
ities.31 These findings indicate that a dysregulated
CX3CR1–FKN axis contributes to disease progression.
Importantly, steatohepatitis is associated with a leaky
gut and intestinal dysbiosis.18,32 However, these studies
could not answer the question of whether an impaired
intestinal barrier is a cause or a consequence. In the pres-
ent study, we showed that loss of Cx3cr1 renders mice
more susceptible toward HFD-induced liver injury,
which was triggered by loss of intestinal barrier integrity.
CX3CR1 is an important regulator of intestinal mac-
rophage homeostasis,14 which is in line with our obser-
vations that the intestinal macrophage populations in
WT and Cx3cr1–/– mice are different. Similar to obser-
vations in dextran sodium sulfate colitis,33 HFD led to a
reduction of CD11b1CD11c1 resident macrophages.
These macrophages have a high phagocytic capacity and
have gatekeeper functions in the intestinal lamina
Fig. 5. The effect of broad-spectrum antibiotics on diet-induced steatohepatitis. (A) NAS, liver-to-body weight ratio, serum ALT levels, and hepatic tri-
glyceride levels in WT and Cx3cr1–/– mice on NCD and HFD, with and without antibiotic treatment. (B) Hematoxylin and eosin and oil red O staining for
lipid accumulation. (C) Oral glucose tolerance test and area under the curve after 0, 15, 30, 60, and 120 minutes. (NCD and HFD groups without anti-
biotic treatment are similar to Fig. 1). Data are expressed as the mean 6 standard error of the mean and considered significant at *P< 0.05,
**P< 0.01, and ***P< 0.001, respectively. *Significantly different from the resp. control group upon NCD, unless indicated differently. Abbreviations:
ABx, antibiotics; AUC, area under the curve; HE, hematoxylin and eosin; OGTT, oral glucose tolerance test; ORO, oil red O.
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Fig. 6. The hepatic innate immune response upon antibiotic treatment. (A) TLR4 immunoblotting and gene expression in livers of WT and
Cx3cr1–/– mice on NCD and HFD, with and without antibiotic treatment. (B) Hepatic gene expression of the inflammasome components Nlrp3 and
Casp1 and cytokine levels of IL1b in whole-liver lysates of WT and Cx3cr1–/– mice. (C) Flow-cytometric analysis of the infiltrating inflammatory mac-
rophages (CD11bhiF4/80low) in livers of WT and Cx3cr1–/– mice. (D) Immunofluorescent staining against CD11b in livers of WT and Cx3cr1–/– mice
on HFD, with and without antibiotic treatment. (E) Hepatic gene expression of Mcp1. (F) Flow-cytometric analysis of the “restorative” surface markers
CD2061 and CD1241 on the CD11bhiF4/80low macrophages. (NCD and HFD groups without antibiotic treatment are similar to Fig. 2.) Data are
expressed as the mean 6 standard error of the mean and considered significant at *P< 0.05, **P< 0.01, and ***P< 0.001, respectively. *Sig-
nificantly different from the resp. control group upon NCD, unless indicated differently. Abbreviations: ABx, antibiotics; DAPI, 40,6-diamidino-2-phenyl-
indole; FSC-A, forward scatter-area; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SSC-A, side scatter-area.
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propria, thereby limiting translocation of PAMPs to the
portal vein.34 As these macrophages are the main source
of tumor necrosis factor,35 the reduced tumor necrosis
factor levels in our study are most likely a result of the
reduction in this protective macrophage subset. Collec-
tively, a balanced milieu between proinflammatory and
anti-inflammatory stimuli is necessary for intestinal
homeostasis, thereby maintaining the physiological
mononuclear phagocyte subsets and barrier integrity.
One hallmark of intestinal macrophages is a profound
inflammatory anergy toward PAMPs.36 Because we
observed marked differences in macrophage number
and distribution in the intestine upon HFD, we investi-
gated the role of CX3CR1 signaling in macrophages in
general. Our in vitro data in BMDMs revealed that
blocking Cx3cr1 sensitizes macrophages to inflamma-
some activation. Recent data also indicate that inflam-
masome activation is linked to NASH progression.37,38
In contrast to these findings, Henao-Mejia et al. demon-
strated that inflammasome activation can negatively reg-
ulate NASH progression through alterations in the gut
microbiota.39 Furthermore, inflammasome activation is
also able to regulate intestinal homeostasis during dex-
tran sodium sulfate–induced colitis and goblet cell
mucus secretion in mice, thereby protecting the intesti-
nal integrity and making cells sensitive for clearance of
enteric pathogens from the mucosal surface.40-42
Together, these data demonstrate that a tight regulation
of inflammasome-mediated innate immunity plays an
important role in intestinal homeostasis and that
CX3CR1 is an essential gatekeeper in controlling this
process.
Besides being the central organ of metabolism, the
liver is also the first site that encounters PAMPs through
the portal circulation. Therefore, the liver is particularly
enriched with innate immune cells, which points toward
a role of CX3CR1 in mediating the innate immune
response upon metabolic disorders. Recent findings
showed that Cx3cr1–/– mice had less glucose intolerance
after 10 weeks of HFD, which was attributed to reduced
white adipose tissue inflammation, a major cause of
insulin resistance.43 In contrast, Lee et al. found that
Cx3cr1–/– mice were more prone to develop glucose
intolerance after 16 weeks of HFD feeding,5 which is
also supported by our findings, demonstrating that
Cx3cr1–/– mice have higher fasting glucose levels and
stronger glucose intolerance compared to WT mice.
These contradictory data regarding glucose intolerance
in Cx3cr1–/– mice might be attributed to differences in
intestinal microbiota composition. Our microbiota
analysis revealed that Cx3cr1–/– mice on HFD showed a
pattern that was recently linked to insulin resistance44—
overgrowth of Bacteroides and reduction of Akkermansia
muciniphila.
The gut–liver crosstalk in our study also suggested a
pronounced pathogen recognition receptor–mediated
inflammatory response. Similarly, it has been demon-
strated that TLR4-mediated hepatic inflammation can
suppress insulin signaling by inhibiting AKT phospho-
rylation.45 Therefore, alterations in microbiota compo-
sition and hepatic inflammation might explain the
susceptibility and/or progression toward insulin resist-
ance in Cx3cr1–/– mice. In line with these findings, anti-
biotic treatment abrogated the inflammatory response in
our Cx3cr1–/– mice upon HFD and led to improved
glucose tolerance. Because inflammasome activation is
highlighted in multiple manifestations of the metabolic
syndrome,46 it was demonstrated that NLRP3-mediated
release of IL1b is promoting insulin resistance,47,48
beta-cell death,49 and atherosclerotic plaque forma-
tion.50 Collectively, these data indicate that inflamma-
some regulation through CX3CR1 and gut–liver
interactions are central for the development of the meta-
bolic syndrome.
In summary, our data demonstrate the functional
relevance of the CX3CR1–FKN axis in the pathogenesis
of NASH (Supporting Fig. S7). CX3CR1 limits the
progression of steatohepatitis and the onset of glucose
intolerance by maintaining intestinal barrier integrity.
Strikingly, this effect was dependent on the intestinal
microbiota composition as antibiotic treatment could
rescue the NASH phenotype in Cx3cr1–/– mice. Our
study extends the growing knowledge about the central
role of various chemokines in the pathogenesis of
NASH. We identified the chemokine receptor CX3CR1
as a gatekeeper of diet-induced steatohepatitis by main-
taining intestinal homeostasis. Therefore, future studies
are warranted to assess the potential modulation of che-
mokines and their receptors to treat patients with
NASH. Hence, our data identified CX3CR1 as a gate-
keeper and potential therapeutic target of diet-induced
steatohepatitis.
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